The interaction between thyroid dysfunction and diabetes is bidirectional, and L-thyroxine treatment may significantly improve insulin sensitivity in patients with hypothyroidism and insulin resistance, suggesting that modulating thyroid status could be a potential strategy for reducing NAFLD risk (31, 32). The gene discussed is INS; the disease is metabolic dysfunction-associated steatotic liver disease.